Literature DB >> 11592849

Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome.

E Head1, W Garzon-Rodriguez, J K Johnson, I T Lott, C W Cotman, C Glabe.   

Abstract

The processes involved with beta-amyloid (Abeta) degradation and clearance in human brain are not well understood. We hypothesized that the distribution of oxidatively modified Abeta, as determined by an affinity-purified antibody in the entorhinal and frontal cortices of Alzheimer's disease (AD), Down syndrome (DS), nondemented elderly control cases, and canine brain, would provide insight into the mechanisms of Abeta accumulation. Based upon plaque counts, oxidized Abeta was present within 46-48% of diffuse and primitive plaques and 98% of cored plaques. Dense punctate deposits of oxidized Abeta were distributed throughout the neuropil in AD and DS brains but were also present within controls with mild neuropathology and isolated cognitive impairments. Confocal studies indicate that punctate oxidized Abeta deposits were within activated microglia. Oxidatively modified Abeta may reflect the efforts of microglial cells to take up and degrade Abeta. Oxidative modification of Abeta may be an early event in Abeta pathogenesis and may be important for plaque biogenesis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592849     DOI: 10.1006/nbdi.2001.0431

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  22 in total

1.  Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

Authors:  Giovanna Cenini; Amy L S Dowling; Tina L Beckett; Eugenio Barone; Cesare Mancuso; Michael Paul Murphy; Harry Levine; Ira T Lott; Frederick A Schmitt; D Allan Butterfield; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2011-10-08

Review 2.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.

Authors:  Erik S Musiek; David M Holtzman
Journal:  Nat Neurosci       Date:  2015-06       Impact factor: 24.884

3.  Designer receptors enhance memory in a mouse model of Down syndrome.

Authors:  Ashley M Fortress; Eric D Hamlett; Elena M Vazey; Gary Aston-Jones; Wayne A Cass; Heather A Boger; Ann-Charlotte E Granholm
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

Review 4.  Antioxidants in Down syndrome.

Authors:  Ira T Lott
Journal:  Biochim Biophys Acta       Date:  2011-12-21

Review 5.  Down syndrome, beta-amyloid and neuroimaging.

Authors:  Elizabeth Head; Alex M Helman; David Powell; Frederick A Schmitt
Journal:  Free Radic Biol Med       Date:  2017-09-19       Impact factor: 7.376

Review 6.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

7.  Endogenous zinc in neurological diseases.

Authors:  Jae-Yong Koh
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

8.  Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.

Authors:  Irina Petrushina; Anahit Ghochikyan; Mikayel Mktrichyan; Gregory Mamikonyan; Nina Movsesyan; Hayk Davtyan; Archita Patel; Elizabeth Head; David H Cribbs; Michael G Agadjanyan
Journal:  J Neurosci       Date:  2007-11-14       Impact factor: 6.167

9.  Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's disease.

Authors:  Xiaoying Guan; Junhua Yang; Huaiyu Gu; Juntao Zou; Zhibin Yao
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

Review 10.  Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.

Authors:  D Allan Butterfield; Fabio Di Domenico; Aaron M Swomley; Elizabeth Head; Marzia Perluigi
Journal:  Biochem J       Date:  2014-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.